antibody

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

December 30, 2025 09:15 ET  | Source: Akari Therapeutics Plc TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) --…

1 week ago

Pictor’s Test Poised to Transform Hepatitis B Immunity Testing Amid CDC Guidance Shifts

CARLSBAD, Calif., Dec. 19, 2025 /PRNewswire/ -- With the CDC's Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testing…

3 weeks ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing…

3 weeks ago

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II…

2 months ago

Study Finds ELISAs in Milk Samples Less Reliable for Johne’s Disease Detection — $198M in Dairy Losses Underscore Need for More Accurate Milk Testing

Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance…

2 months ago

Jubilant Biosys Limited Seals Deal with Pierre Fabre SA

To acquire R&D center at Saint-Julien-en-Genevois, France To add Drug Discovery & Preclinical Development capabilities in Biologics & Antibody Drug…

3 months ago

Benchling Reveals the Next Chapter of R&D at Benchtalk 2025

Benchling AI debuts alongside major new capabilities for antibody discovery, automated data analysis, and development BOSTON, Oct. 14, 2025 /PRNewswire/…

3 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025 09:00 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

3 months ago

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

5 months ago